Cardiac allograft vasculopathy medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 33: | Line 33: | ||
* This procedure has been studied in multiple clinical trials in patients with refractory angina and those who are not considered as surgical candidates. | * This procedure has been studied in multiple clinical trials in patients with refractory angina and those who are not considered as surgical candidates. | ||
* Mehra and colleagues <ref name="pmid9230169">{{cite journal| author=Malik FS, Mehra MR, Ventura HO, Smart FW, Stapleton DD, Ochsner JL| title=Management of cardiac allograft vasculopathy by transmyocardial laser revascularization. | journal=Am J Cardiol | year= 1997 | volume= 80 | issue= 2 | pages= 224-5 | pmid=9230169 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9230169 }} </ref> first studied the effects of TMLR in patients with diffuse CAV. They reported significant improvement in symptoms and anginal class at 4 and 8 week follow up. However, at 24 month follow up, the procedure showed neither consistent symptomatic improvement nor any change in course of the progression of CAV <ref name="pmid10967275">{{cite journal| author=Mehra MR, Uber PA, Prasad AK, Park MH, Scott RL, McFadden PM et al.| title=Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization: early rewards, late losses. | journal=J Heart Lung Transplant | year= 2000 | volume= 19 | issue= 8 | pages= 801-4 | pmid=10967275 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10967275 }} </ref>. | * Mehra and colleagues <ref name="pmid9230169">{{cite journal| author=Malik FS, Mehra MR, Ventura HO, Smart FW, Stapleton DD, Ochsner JL| title=Management of cardiac allograft vasculopathy by transmyocardial laser revascularization. | journal=Am J Cardiol | year= 1997 | volume= 80 | issue= 2 | pages= 224-5 | pmid=9230169 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9230169 }} </ref> first studied the effects of TMLR in patients with diffuse CAV. They reported significant improvement in symptoms and anginal class at 4 and 8 week follow up. However, at 24 month follow up, the procedure showed neither consistent symptomatic improvement nor any change in course of the progression of CAV <ref name="pmid10967275">{{cite journal| author=Mehra MR, Uber PA, Prasad AK, Park MH, Scott RL, McFadden PM et al.| title=Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization: early rewards, late losses. | journal=J Heart Lung Transplant | year= 2000 | volume= 19 | issue= 8 | pages= 801-4 | pmid=10967275 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10967275 }} </ref>. | ||
====Heparin Induced/Mediated Extracorporeal LDL Plasmapheresis==== | |||
* Also known as LDL apheresis. | |||
* Leads to significant reductions in [[LDL]], [[lipoprotein(a)]] levels and [[fibrinogen]]. | |||
* No effect on [[HDL]] levels. | |||
* In a prospective study by Park et al., patients treated with LDL apheresis had a statistically significant increase in intraluminal diameter between 1 year and 2.5 years of follow up. However, long term trials are required to draw firm conclusions. | |||
==References== | ==References== | ||
Revision as of 22:19, 13 December 2014
|
Cardiac allograft vasculopathy Microchapters |
|
Differentiating Cardiac allograft vasculopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cardiac allograft vasculopathy medical therapy On the Web |
|
American Roentgen Ray Society Images of Cardiac allograft vasculopathy medical therapy |
|
Directions to Hospitals Treating Cardiac allograft vasculopathy |
|
Risk calculators and risk factors for Cardiac allograft vasculopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
Medical Therapy
Pharmacologic Management
Nonpharmacologic Interventions
- Retransplantation
- Percutaneous coronary interventions
- Coronary artery bypass grafting (CABG)
- Transmyocardial revascularization
- Heparin induced/mediated extracorporeal LDL plasmapheresis (HELP)
Retransplantation
- Retransplantation is the only definitive treatment for CAV. It is associated with satisfactory survival in patients with CAV.
- About 60% of the repeat transplantation procedures performed are due to graft failure secondary to CAV [1]. It is a higher risk procedure and raises significant ethical concerns primarily because of scarcity of heart transplant donors [2].
- Prognosis: One year survival has improved in recent years, but continues to be inferior compared to primary transplants (79% in re-transplant group compared to 85% in primary transplant group) [3].
Percutaneous Coronary Intervention
- This procedure is limited only to a selected group of patients with focal disease in a single artery. Moreover, the number of patients who benefit are small.
- Incidence of re-stenosis is high, ranging from 20 to 60% as reported in various studies.
- Intracoronary stenting appears to have lower rate of re-stenosis as compared to coronary angioplasty alone.
- Concomitant use of high dose immunosuppressive therapy with azathioprine and mycophenolate have shown to significantly reduce the rate of re-stenosis [4].
Coronary Artery Bypass Grafting
- Associated with a high perioperative mortality especially in those with distal disease.
- In a retrospective analysis of 12 patients with CAV who underwent CABG, 4 died perioperatively, while only 7 were alive at the end of 9 months post-surgery [5].
Transmyocardial Revascularization
- Also known as transmyocardial laser revascularization (TMLR), is a procedure involving creation of transmural channels in the myocardium to enhance blood supply.
- This procedure has been studied in multiple clinical trials in patients with refractory angina and those who are not considered as surgical candidates.
- Mehra and colleagues [6] first studied the effects of TMLR in patients with diffuse CAV. They reported significant improvement in symptoms and anginal class at 4 and 8 week follow up. However, at 24 month follow up, the procedure showed neither consistent symptomatic improvement nor any change in course of the progression of CAV [7].
Heparin Induced/Mediated Extracorporeal LDL Plasmapheresis
- Also known as LDL apheresis.
- Leads to significant reductions in LDL, lipoprotein(a) levels and fibrinogen.
- No effect on HDL levels.
- In a prospective study by Park et al., patients treated with LDL apheresis had a statistically significant increase in intraluminal diameter between 1 year and 2.5 years of follow up. However, long term trials are required to draw firm conclusions.
References
- ↑ Mehra MR (2006). "Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy". Am J Transplant. 6 (6): 1248–56. doi:10.1111/j.1600-6143.2006.01314.x. PMID 16686747.
- ↑ Radovancevic B, McGiffin DC, Kobashigawa JA, Cintron GB, Mullen GM, Pitts DE; et al. (2003). "Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study". J Heart Lung Transplant. 22 (8): 862–8. PMID 12909465.
- ↑ Srivastava R, Keck BM, Bennett LE, Hosenpud JD (2000). "The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry". Transplantation. 70 (4): 606–12. PMID 10972218.
- ↑ Benza RL, Zoghbi GJ, Tallaj J, Brown R, Kirklin JK, Hubbard M; et al. (2004). "Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience". J Am Coll Cardiol. 43 (11): 1973–81. doi:10.1016/j.jacc.2004.02.045. PMID 15172400.
- ↑ Halle AA, DiSciascio G, Massin EK, Wilson RF, Johnson MR, Sullivan HJ; et al. (1995). "Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients". J Am Coll Cardiol. 26 (1): 120–8. PMID 7797740.
- ↑ Malik FS, Mehra MR, Ventura HO, Smart FW, Stapleton DD, Ochsner JL (1997). "Management of cardiac allograft vasculopathy by transmyocardial laser revascularization". Am J Cardiol. 80 (2): 224–5. PMID 9230169.
- ↑ Mehra MR, Uber PA, Prasad AK, Park MH, Scott RL, McFadden PM; et al. (2000). "Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization: early rewards, late losses". J Heart Lung Transplant. 19 (8): 801–4. PMID 10967275.